about
Epithelial Anion Transport as Modulator of Chemokine SignalingAetiopathogenesis of liver changes in the course of cystic fibrosis, considering disturbances of the bile acid profile as well as genetic and immunological factorsCystic fibrosis related liver disease--another black box in hepatology.Cirrhosis and other liver disease in cystic fibrosis.Liver disease in cystic fibrosis: an updateHepatic and Splenic Acoustic Radiation Force Impulse Shear Wave Velocity Elastography in Children with Liver Disease Associated with Cystic Fibrosis.Assessment of pathologic increase in liver stiffness enables earlier diagnosis of CFLD: Results from a prospective longitudinal cohort studySerum proteome profiling identifies novel and powerful markers of cystic fibrosis liver diseaseCFTR dysfunction predisposes to fibrotic liver disease in a murine modelLung transplantation for cystic fibrosis: results, indications, complications, and controversies.Imaging the Abdominal Manifestations of Cystic Fibrosis.Genome-wide association studies and genetic risk assessment of liver diseases.Ursodeoxycholic acid in cholestasis: linking action mechanisms to therapeutic applications.Transporters in cholelithiasis.Growth and Development Symposium: Development, characterization, and use of a porcine epiblast-derived liver stem cell line: ARS-PICM-19.Lysosomal acid lipase deficiency: a form of non-obese fatty liver disease (NOFLD).A biliary HCO3- umbrella constitutes a protective mechanism against bile acid-induced injury in human cholangiocytes.Knockdown of ezrin causes intrahepatic cholestasis by the dysregulation of bile fluidity in the bile duct epithelium in mice.Dehydrocostuslactone, a sesquiterpene lactone activates wild-type and ΔF508 mutant CFTR chloride channel.Liver transplantation in adult cystic fibrosis: Clinical, imaging, and pathological evidence of obliterative portal venopathy.Risk factors for hepatic steatosis in adults with cystic fibrosis: Similarities to non-alcoholic fatty liver disease.Gastrointestinal Manifestations of Cystic Fibrosis.Single-Center Long-Term Analysis of Combined Liver-Lung Transplant Outcomes.
P2860
Q26744381-554899DD-57F7-4B28-85DD-439321D628C2Q26999270-BB25EC7D-482B-4531-9684-6DDA99CF785CQ28655881-ADDBAE7A-CADC-4659-86C2-6C8BBD304BAFQ28660820-E5391C38-A844-41C1-8721-BF1758FE060FQ28662082-8C1533A8-92E2-47CB-A5F3-A9FC8199B939Q30397913-AAA771CF-AF17-4093-AD09-76E584CAA42AQ33757918-5183E2A8-5B15-4C18-92BC-115F9216D0BBQ34630224-9537E120-B6CC-4B5F-B9CE-53AACF2EF1F9Q36176038-3AD365E6-F36D-4261-A7A2-FC976084B2C8Q36658777-62078F7A-58D9-4AC8-91B0-2B6363BC62E2Q37637314-624CAD4A-7047-4D11-96F5-F730DFE11EB7Q37806616-FF07C883-2CEF-4B83-8A33-AE9DFDBFCB1AQ37919924-E85B8283-8CC6-44EB-8C1E-F970092BC245Q38013076-803FA11C-3600-4855-BD0C-1903FB7FB664Q39245521-630BEEBA-E7C5-4A6D-88BF-482D791F65FCQ39371640-058D225A-5269-4BEF-8C3C-5D2DAE835061Q39471132-548D04B8-6F3A-451D-99DC-83B1017D689CQ41703155-BBDF6745-BF2D-4490-ADB9-311040470826Q44112526-3B20A8AA-CE15-4D2F-9171-9D25E6279249Q48224685-C9C7F710-DC4A-4742-B8DD-6B68F108C6C5Q49334378-25B42D97-052E-4344-B566-75C1CD79C8B2Q53627194-D24038D7-0EDA-4725-AAE8-C9457EB05A4FQ54967602-2831EAB5-EA8A-433D-BD22-79F45AFD56F6
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on October 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cystic fibrosis-associated liver disease.
@en
Cystic fibrosis-associated liver disease.
@nl
type
label
Cystic fibrosis-associated liver disease.
@en
Cystic fibrosis-associated liver disease.
@nl
prefLabel
Cystic fibrosis-associated liver disease.
@en
Cystic fibrosis-associated liver disease.
@nl
P2093
P1476
Cystic fibrosis-associated liver disease.
@en
P2093
Frank Lammert
Gerd Dockter
Ulrike Herrmann
P304
P356
10.1016/J.BPG.2010.08.003
P577
2010-10-01T00:00:00Z